scholarly journals Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 672
Author(s):  
Dmitry Polyakov ◽  
Ekaterina Sinitsyna ◽  
Natalia Grudinina ◽  
Mariia Antipchik ◽  
Rodion Sakhabeev ◽  
...  

Hepatitis C is one of the most common social diseases in the world. The improvements in both the early diagnostics of the hepatitis C and the treatment of acute viremia caused by hepatitis C virus are undoubtedly an urgent task. In present work, we offered the micro- and nanotraps for the capturing of HCV. As a capturing moiety, we designed and synthesized in E. coli a fusion protein consisting of large extracellular loop of CD81 receptor and streptavidin as spacing part. The obtained protein has been immobilized on the surface of PLA-based micro- and nanoparticles. The developed trapping systems were characterized in terms of their physico-chemical properties. In order to illustrate the ability of developed micro- and nanotraps to bind HCV, E2 core protein of HCV was synthesized as a fusion protein with GFP. Interaction of E2 protein and hepatitis C virus-mimicking particles with the developed trapping systems were testified by several methods.

2002 ◽  
Vol 76 (21) ◽  
pp. 11143-11147 ◽  
Author(s):  
Heidi E. Drummer ◽  
Kirilee A. Wilson ◽  
Pantelis Poumbourios

ABSTRACT The binding of hepatitis C virus glycoprotein E2 to the large extracellular loop (LEL) of CD81 has been shown to modulate human T-cell and NK cell activity in vitro. Using random mutagenesis of a chimera of maltose-binding protein and LEL residues 113 to 201, we have determined that the E2-binding site on CD81 comprises residues Ile182, Phe186, Asn184, and Leu162. These findings reveal an E2-binding surface of approximately 806 Å2 and potential target sites for the development of small-molecule inhibitors of E2 binding.


1993 ◽  
Vol 38 (4) ◽  
pp. 626-630 ◽  
Author(s):  
Osamu Yokosuka ◽  
Yoshimi Ito ◽  
Jun Sakuma ◽  
Fumio Imazeki ◽  
Masao Ohto ◽  
...  

2006 ◽  
Vol 80 (22) ◽  
pp. 11265-11273 ◽  
Author(s):  
Kousuke Nakai ◽  
Toru Okamoto ◽  
Tomomi Kimura-Someya ◽  
Koji Ishii ◽  
Chang Kweng Lim ◽  
...  

ABSTRACT Hepatitis C virus (HCV) contains two membrane-associated envelope glycoproteins, E1 and E2, which assemble as a heterodimer in the endoplasmic reticulum (ER). In this study, predictive algorithms and genetic analyses of deletion mutants and glycosylation site variants of the E1 glycoprotein were used to suggest that the glycoprotein can adopt two topologies in the ER membrane: the conventional type I membrane topology and a polytopic topology in which the protein spans the ER membrane twice with an intervening cytoplasmic loop (amino acid residues 288 to 360). We also demonstrate that the E1 glycoprotein is able to associate with the HCV core protein, but only upon oligomerization of the core protein in the presence of tRNA to form capsid-like structures. Yeast two-hybrid and immunoprecipitation analyses reveal that oligomerization of the core protein is promoted by amino acid residues 72 to 91 in the core. Furthermore, the association between the E1 glycoprotein and the assembled core can be recapitulated using a fusion protein containing the putative cytoplasmic loop of the E1 glycoprotein. This fusion protein is also able to compete with the intact E1 glycoprotein for binding to the core. Mutagenesis of the cytoplasmic loop of E1 was used to define a region of four amino acids (residues 312 to 315) that is important for interaction with the assembled HCV core. Taken together, our studies suggest that interaction between the self-oligomerized HCV core and the E1 glycoprotein is mediated through the cytoplasmic loop present in a polytopic form of the E1 glycoprotein.


Viruses ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 207 ◽  
Author(s):  
Pia Banse ◽  
Rebecca Moeller ◽  
Janina Bruening ◽  
Lisa Lasswitz ◽  
Sina Kahl ◽  
...  

2012 ◽  
Vol 87 (3) ◽  
pp. 1605-1617 ◽  
Author(s):  
Ahmed Wahid ◽  
François Helle ◽  
Véronique Descamps ◽  
Gilles Duverlie ◽  
François Penin ◽  
...  

ABSTRACTClass II membrane fusion proteins have been described in viruses in which the envelope proteins are derived from a precursor polyprotein containing two transmembrane glycoproteins arranged in tandem. Although the second protein, which carries the membrane fusion function, is in general well characterized, the companion protein, which is a protein chaperone for the folding of the fusion protein, is less well characterized for some viruses, like hepatitis C virus (HCV). To investigate the role of the class II companion glycoprotein E1 of HCV, we chose to target conserved cysteine residues in the protein, and we systematically mutated them in a full-length infectious HCV clone by reverse genetics. All the mutants were infectious, albeit with lower titers than the wild-type virus. The reduced infectivity was in part due to a decrease in viral assembly, as revealed by measurement of intracellular infectivity and by quantification of core protein released from cells transfected with mutant genomes. Analyses of mutated proteins did not show any major defect in folding. However, the mutations reduced virus stability, and they could also affect the density of infectious viral particles. Mutant viruses also showed a defect in cell-to-cell transmission. Finally, our data indicate that HCV glycoprotein E1 can also affect the fusion protein E2 by modulating its recognition by the cellular coreceptor CD81. Therefore, in the context of HCV, our data identify an additional function of a class II companion protein as a molecule that can control the binding capacity of the fusion protein.


Structure ◽  
2018 ◽  
Vol 26 (1) ◽  
pp. 181 ◽  
Author(s):  
Eva S. Cunha ◽  
Pedro Sfriso ◽  
Adriana L. Rojas ◽  
Pietro Roversi ◽  
Adam Hospital ◽  
...  

2006 ◽  
Vol 80 (22) ◽  
pp. 11331-11342 ◽  
Author(s):  
Mike Flint ◽  
Thomas von Hahn ◽  
Jie Zhang ◽  
Michelle Farquhar ◽  
Christopher T. Jones ◽  
...  

ABSTRACT Hepatitis C virus (HCV) entry is dependent on CD81. To investigate whether the CD81 sequence is a determinant of HCV host range, we expressed a panel of diverse CD81 proteins and tested their ability to interact with HCV. CD81 large extracellular loop (LEL) sequences were expressed as recombinant proteins; the human and, to a low level, the African green monkey sequences bound soluble HCV E2 (sE2) and inhibited infection by retrovirus pseudotype particles bearing HCV glycoproteins (HCVpp). In contrast, mouse or rat CD81 proteins failed to bind sE2 or to inhibit HCVpp infection. However, CD81 proteins from all species, when expressed in HepG2 cells, conferred susceptibility to infection by HCVpp and cell culture-grown HCV to various levels, with the rat sequence being the least efficient. Recombinant human CD81 LEL inhibited HCVpp infectivity only if present during the virus-cell incubation, consistent with a role for CD81 after virus attachment. Amino acid changes that abrogate sE2 binding (I182F, N184Y, and F186S, alone or in combination) were introduced into human CD81. All three amino acid changes in human CD81 resulted in a molecule that still supported HCVpp infection, albeit with reduced efficiency. In summary, there is a remarkable plasticity in the range of CD81 sequences that can support HCV entry, suggesting that CD81 polymorphism may contribute to, but alone does not define, the HCV susceptibility of a species. In addition, the capacity to support viral entry is only partially reflected by assays measuring sE2 interaction with recombinant or full-length CD81 proteins.


2009 ◽  
Vol 15 (2) ◽  
pp. 240 ◽  
Author(s):  
Zhan-Fei Tian ◽  
Hong Shen ◽  
Xi-Hua Fu ◽  
Yi-Chun Chen ◽  
Hubert E Blum ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document